The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...